Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ertapenem
Drug ID BADD_D00802
Description Ertapenem is a carbapenem antibiotic drug that is marketed under the trade name Invanz by Merck & Co. pharmaceutical company. It is structurally similar to [meropenem] and possesses a 1-beta-methyl group.
Indications and Usage For the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, or Bacteroides uniformis, (2) complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus species, Porphyromonas asaccharolytica, or Prevotella bivia, (3) community acquired pneumonia due to Streptococcus pneumoniae (penicillin susceptible isolates only) including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis, (4) complicated urinary tract infections including pyelonephritis due to Escherichia coli, including cases with concurrent bacteremia, or Klebsiella pneumoniae, (5) acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections due to Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia.
Marketing Status approved; investigational
ATC Code J01DH03
DrugBank ID DB00303
KEGG ID D07908
MeSH ID D000077727
PubChem ID 150610
TTD Drug ID D0Q1MS
NDC Product Code 43598-901; 55150-282; 0409-3510; 16714-889; 44567-820
UNII G32F6EID2H
Synonyms Ertapenem | Invanoz | Invanz | Ertapenem Sodium
Chemical Information
Molecular Formula C22H25N3O7S
CAS Registry Number 153832-46-3
SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tonic clonic movements17.12.03.0060.000049%Not Available
Respiratory tract congestion22.02.07.003--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal stiffness15.03.05.0270.000049%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Clonic convulsion17.12.03.0080.000049%Not Available
Infusion site induration08.02.05.009; 12.07.05.010--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site warmth12.07.05.012; 08.02.05.011--Not Available
Infusion site swelling12.07.05.003; 08.02.05.002--Not Available
Infusion site phlebitis24.12.03.002; 12.07.05.004; 08.02.05.003--Not Available
Infusion site pruritus23.03.12.006; 12.07.05.005; 08.02.05.004--Not Available
Wound complication23.03.11.044; 12.01.08.010--
Acquired haemophilia01.01.01.0020.000049%Not Available
Infusion site oedema12.07.05.013; 08.02.05.012--Not Available
Infusion site reaction08.02.05.005; 12.07.05.006--Not Available
Haemorrhage24.07.01.0020.000122%Not Available
Vulvovaginal pruritus23.03.12.009; 21.08.02.004--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000107%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000122%Not Available
Clostridium colitis11.02.02.005; 07.19.01.011--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Bicytopenia01.03.03.0100.000049%Not Available
Incision site complication12.02.05.012--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000131%Not Available
Induration08.01.03.020--Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages